Delta Air Lines announces December quarter and full year 2025 financial results, with premium cabin revenue surpassing economy revenue for the first time ever, even as overall passenger counts held steady. The shift highlights growing demand for higher-yield seats amid a recovering travel market.

A clean earnings beat caps JPMorgan’s strong 2025, but Trump’s pressure campaign injects new uncertainty into the outlook. Management points to trading revenue strength and expense discipline as shields against murky regulatory talk.

BP Plc said it expects to take as much as $5 billion in writedowns for the fourth quarter, weeks after swapping its CEO as it strives to turn around its energy-transition strategy. The move underscores the mounting costs of shifting away from fossil fuels.

The brief Ethena relief rally at the start of the month has faltered, and traders can maintain a bearish bias. The recent partnerships haven’t shifted the downtrend, leaving ENA vulnerable to a breakdown if support zones fail.

Bitcoin hits $95,000 for the first time in nearly two months as short liquidations near $250 million. The surge fueled a classic short squeeze, leaving doubters scrambling to cover and reigniting momentum trading in crypto.

BOSTON, Jan. 13, 2026 – Praxis Precision Medicines, a leading CNS biopharmaceutical company, announced the appointment of world-renowned neurologist Dr. Orrin Devinsky to steer clinical strategy. The hire signals a push into novel epilepsy treatments backed by precision neuroscience.

Monero breaks into all-time-high territory while Dash records its largest move since October. The privacy sector is heating up—here’s what’s driving it, from regulatory arbitrage to renewed demand for untraceable transactions.

GameStop used to dominate retail gaming, but this announcement highlights how digital distribution and store closures are turning it into a shadow of its former self. The latest plan may be too little, too late.

The total market size of systemic lupus erythematosus is expected to expand in the 7MM through 2034, driven by biologics like BENLYSTA and SAPHNELO and a robust clinical pipeline including nipocalimab and Litifilimab.

The radiopharmaceuticals market is entering an era of high-capacity infrastructure investment, with facilities in Wisconsin and Germany expanding production of Ac-225 and Lu-177 to meet rising demand for targeted cancer therapies.

Gold and silver hit records on Tuesday after a weaker-than-expected US inflation reading, while markets kept a close eye on renewed attacks on Fed independence amid reports of a criminal probe into central-bank lending programs.

The genomic testing market is shifting toward continuous health monitoring. By 2035, routine liquid biopsies and multiomics will democratize access to precision medicine and drive a $41.34 billion market.

XTL Biopharmaceuticals acquired an 85% stake in NeuroNOS, backed by two Nobel laureates and founder Prof. Haitham Amal, aiming to tap into the $30+ billion autism therapy market with cutting-edge scientific leadership.

This partnership enables broader adoption of FemaSeed through a trusted community health provider, bringing first-line treatment for uterine conditions to a large, engaged patient population outside hospital settings.

The final week of December saw the same conditions that DASH is experiencing now, with a spike driven by privacy-sector momentum but no clear breakout confirmed. Traders should watch key support levels.